US 11,951,097 B2
Methods of treating multiple sclerosis
Allitia DiBernardo, Philadelphia, PA (US); Tatiana Sidorenko, Allschwil (CH); Michel Burcklen, Allschwil (CH); Sivi Ouwerkerk-Mahadevan, Beerse (BE); Andrea Vaclavkova, Allschwil (CH); Brian Patrick Hennessy, Geneva (CH); and Hilke Kracker, Weil am Rhein (DE)
Assigned to Vanda Pharmaceuticals Inc., Washington, DC (US)
Filed by Vanda Pharmaceuticals Inc., Washington, DC (US)
Filed on Oct. 10, 2022, as Appl. No. 17/962,968.
Claims priority of provisional application 63/254,369, filed on Oct. 11, 2021.
Prior Publication US 2023/0143217 A1, May 11, 2023
Int. Cl. A61K 31/426 (2006.01); A61K 9/00 (2006.01); A61K 31/138 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/426 (2013.01) [A61P 25/28 (2018.01); A61K 9/0053 (2013.01); A61K 31/138 (2013.01)] 29 Claims
 
1. A method for reducing clinical management events before or during treatment of multiple sclerosis in a patient in need thereof, comprising administering ponesimod in an amount and manner that is described in a drug product label for an approved drug product.